Arteriosclerosis
Not recruitingStudy on Inclisiran for Preventing Heart Disease in High-Risk Patients
- Disease:Arteriosclerosis
- Substances:Inclisiran
Hungary- Participants:18–64 years · 65+ years
- Substances:Inclisiran
- Sponsor:Novartis Pharma AG
Rare diseases
Investigational molecules
Locations
Back to Hungary1 clinical trial in Hosszuheteny, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.
HungaryThe busiest research cities in the country
What the registry says about research in the country
Groundbreaking clinical trials focusing on atherosclerotic cardiovascular disease prevention are currently underway. These studies aim to evaluate innovative therapeutic approaches for reducing major adverse cardiovascular events in high-risk patients.
The research specifically targets patients requiring preventive care for ASCVD, investigating treatments that could significantly impact cardiovascular mortality and morbidity rates.
Tell us about your condition – we search every trial in Europe and connect you with the right site.